Sponsors

Improved assessment of chronic kidney disease

Hospital laboratories rely on the Roche enzymatic creatinine assay for specific and reliable results The Roche Creatinine Plus assay, for use with cobas or MODULAR Analytics analysers, offers a specific and accurate alternative to the less-specific Jaffé method, ensuring clinically more reliable results in the management of patients with chronic kidney disease (CKD).

Creatinine levels in serum or plasma are used to calculate the estimated
glomerular filtration rate, using the recommended ‘modification of diet in renal disease’ (MDRD) formula, in order to identify and monitor patients with stage 3–5 CKD, as required by the Department of Health Quality and Outcomes Framework.

Recently, users at GSTS (Guy’s, St Thomas’, Serco) Pathology, London, and the University Hospital, Coventry, among others, have found that the Roche Creatinine Plus assay provides more accurate assessment of renal function, thereby helping to improve patient care and offering a cost-effective alternative to less-specific methods.

www.roche-diagnostics.co.uk

Latest Issues

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024

11th Digital Pathology & AI Congress: Europe

Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024

Microbiology Society Annual Conference 2025

Liverpool Arena and Convention Centre
31 March - 3 April, 2025

BSMT Annual Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

Ghent Pathology 2025

ICC Ghent, Belgium
24-26 June, 2025